Table 2.

Associations between the NUGs of three independent SNPs with NSCLC OS and DSS in the PLCO Trial.

Genotype	Frequency	OS a			DSS a
		Death (%)	HR (95% CI)	P	Death (%)	HR (95% CI)	P
LRRC8C rs10493829 T>C b
TT	372	257 (60.09)	1.00	–	229 (61.56)	1.00	–
TC	557	377 (67.68)	0.94(0.80-1.10)	0.442	337 (60.50)	0.94 (0.80-1.12)	0.502
CC	246	155 (63.01)	0.69 (0.56-0.84)	0.0003	143 (58.13)	0.72 (0.58-0.89)	0.003
Trend test				0.0005			0.0001
Dominant
TT	372	257 (60.09)	1.00	–	229 (61.56)	1.00	–
TC+CC	803	532 (66.25)	0.85 (0.73-0.99)	0.035	480 (59.78)	0.87 (0.74-1.02)	0.075
Or reverse
TC+CC	803	532 (66.25)	1.00	–	480 (59.78)	1.00	–
TT	372	257 (60.09)	1.18 (1.01-1.37)	0.035	229 (61.56)	1.16 (0.99-1.35)	0.075
OAS2 rs2239193 A>G c
AA	1029	682 (66.28)	1.00	–	609 (59.18)	1.00	–
AG	141	103 (73.05)	1.36 (1.10-1.68)	0.004	97 (68.79)	1.43 (1.15-1.78)	0.002
GG	3	2 (66.67)	2.62 (0.64-10.75)	0.180	1 (33.33)	1.76 (0.24-12.69)	0.575
Trend test				0.002			0.002
Dominant
AA	1029	682 (66.28)	1.00	–	609 (59.18)	1.00	–
AG+GG	144	105 (72.92)	1.38 (1.11-1.70)	0.003	98 (68.06)	1.43 (1.15-1.78)	0.001
CCL25 rs3136651 T>A d
TT	798	538 (67.42)	1.00	–	485 (60.78)	1.00	–
TA	330	224 (67.88)	0.89 (0.76-1.04)	0.149	199 (60.30)	0.88 (0.75-1.04)	0.139
AA	33	15 (45.45)	0.42 (0.25-0.71)	0.001	14 (42.42)	0.49 (0.29-0.85)	0.011
Trend test				0.003			0.009
Dominant
TT	798	538 (67.42)	1.00	–	485 (60.78)	1.00	–
TA+AA  Or reverse	363	239 (65.84)	0.84 (0.72-0.98)	0.024	213 (58.68)	0.84 (0.72-0.99)	0.037
TA+AA	363	239 (65.84)	1.00		213 (58.68)	1.00
TT	798	538 (67.42)	1.20 (1.02- 1.40)	0.024	485 (60.78)	1.19 (1.01-1.40)	0.037
NUG e
0	226	143 (63.27)	1.00	–	133 (58.85)	1.00	–
1	590	393 (66.61)	1.13 (0.93-1.38)	0.206	342 (57.97)	1.05 (0.86-1.29)	0.616
2	312	217 (69.55)	1.45 (1.17-1.79)	0.0007	199 (63.78)	1.40 (1.12-1.75)	0.003
3	31	22 (70.97)	1.80 (1.12-2.89)	0.015	22 (70.97)	1.95 (1.21-3.13)	0.006
Trend test				<0.0001			0.0002
Dichotomized NUG
0-1	816	536 (65.69)	1.00	–	475 (58.21)	1.00	–
2-3	343	239 (69.68)	1.35 (1.15-1.58)	0.0002	221 (64.43)	1.39 (1.18-1.63)	<0.0001

SNP, single nucleotide polymorphism; NSCLC, non-small cell lung cancer; OS, overall survival; DSS, disease-specific survival. PLCO, Prostate, Lung, Colorectal and Ovarian cancer screening trial; HR, hazards ratio; CI, confidence interval; NPA, number of protective alleles.

^aAdjusted for age, sex, smoking status, histology, tumor stage, chemotherapy, surgery, radiotherapy and principal components.

^b10 with missing data were excluded.

^c12 with missing data were excluded.

^d24 with missing data were excluded.

^eUnfavorable genotypes were LRRC8C rs10493829 TT, OAS2 rs2239193 AG+GG, and CCL25 rs3136651 TT and their results are in bold.